All Blogs

Jan 21, 2025

FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer Amgen has secured FDA approval for LUMAKRAS (sotorasib) in combination with VECTIBIX (panitumumab) as a treatment for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxalip...

Jan 20, 2025

Thyroid eye disease is a rare but serious autoimmune condition that affects the eyes, often linked to hyperthyroidism or Graves’ disease. Around 25-50% of people with Graves’ disease develop TED, with women being more commonly affected than men.  There were 1.4 million diagnosed prevalent cases of TED in 20...

Jan 17, 2025

Affecting around 1 in 200 people, Graves’ disease is the most common cause of an overactive thyroid. More than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. As per DelveInsight’s estimates, Graves’ disease...

Jan 17, 2025

Acute Kidney Injury (AKI) is a significant medical condition that affects millions of individuals worldwide each year. It is a rapidly progressive condition that requires timely diagnosis and treatment to prevent severe complications or long-term consequences. AKI is particularly prevalent in hospitalized patients,...

Jan 16, 2025

Acute kidney injury is a sudden and severe condition characterized by the rapid loss of kidney function, resulting in the accumulation of waste products in the blood and imbalances in fluids and electrolytes. It is often caused by factors such as severe dehydration, infections, certain medications, or complications...

Jan 16, 2025

Johnson & Johnson MedTech Announced CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCHTM SF Catheter, Bolstering Capabilities in Cardiac Arrhythmias Treatment  On January 10, 2025, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the receipt of European CE ma...

Jan 15, 2025

The healthcare industry has undergone a significant transformation over the past few decades, driven in large part by technological advancements. One of the most pivotal innovations in this transformation is the Electronic Health Record (EHR), which has revolutionized how healthcare providers manage patient informa...

Jan 14, 2025

FDA Accepts Agios’ SNDA for PYRUKYND in Thalassemia Patients Agios Pharmaceuticals, Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) to treat adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The appl...

Jan 13, 2025

Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies. With its groundbreaking advancements, the company has redefined the potential of molecular glues in oncology, offering innovative solutions that precisely degrade harmful proteins. Bristo...

Jan 09, 2025

Roche's Momentum in Digital Pathology Continued With FDA Clearance on its High-Volume Slide Scanner  On January 09, 2025, Roche announced that its whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the United States Food and Drug Administration (FDA). This c...